Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg have an estimated market size of US$ 244 million for twelve months ending June 2020 according to IQVIA. Alembic is currently in litigation with Boehringer in District Court of Delaware and launch of the product will depend on litigation outcome.
Alembic now has a total of 130 ANDA approvals (113 final approvals and 17 tentative approvals) from USFDA.